NewsSource: EClinCloud Official Website Historical Archive

Good News: EClinCloud Named to the 2026 Future Healthcare 100 "Innovative Health Services and Industry Chain Services Top 100"

1 min readEClinCloud Editorial Team
Archive article cover: Good News: EClinCloud Named to the 2026 Future Healthcare 100 "Innovative Health Services and Industry Chain Services Top 100"

On the morning of May 21, the VB100 Awards Ceremony of the 2026 Future Healthcare 100 Conference was held in Shanghai, where the 2026 Future Healthcare 100 list was officially released. Based on its AI innovation capabilities in clinical research, EClinCloud was selected for the "Innovative Health Services and Industry Chain Services Top 100" list.

一临云入选2026创新健康服务与产业链服务榜TOP100图示

Recognized by the Industry and Capital Markets

Founded in 2015 and jointly initiated by VB100, VCBeat, and VCBeat Research, the Future Healthcare 100 selection is one of the most influential industry lists and investment bellwethers in China's healthcare sector.

The selection consistently focuses on innovative technologies, industrial value, and growth potential, aiming to identify core innovators representing the future direction of healthcare in China. In 2026, centered on "showcasing, trading, and empowering China's healthcare innovation assets," the selection conducted a comprehensive assessment based on multiple changes in the industry landscape and innovation logic.

This selection fully demonstrates that EClinCloud's overall strength and future potential have earned recognition from both the industry and capital markets.

As an AI technology company in the clinical research field, EClinCloud consistently focuses on real-world pain points across the entire clinical research process and has built a value loop from data to evidence across core products—including eCOA, IRC, EDC, RTSM, CTMS, and eTMF—as well as endpoint assessment services.

This honor stems from the industry's recognition of EClinCloud's professional capabilities and continued exploration. Going forward, we will continue to be driven by AI technology, deepen our focus on clinical research scenarios, and continuously iterate our products and services to support high-quality development in clinical research.

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.